| 高鹏举,罗国刚,李 强,宋海英,牛向宏,张 勃.不同剂量甲钴胺联合GM1治疗糖尿病周围神经病变疗效观察[J].现代生物医学进展英文版,2017,17(21):4108-4111. |
| 不同剂量甲钴胺联合GM1治疗糖尿病周围神经病变疗效观察 |
| Clinical Effect of Different Dose of Methyl Cobalamin Combined GM1 in Treatment of Diabetic Peripheral Neuropathy Patients |
| Received:November 23, 2016 Revised:December 21, 2016 |
| DOI：10.13241/j.cnki.pmb.2017.21.027 |
| 中文关键词: 糖尿病周围神经病变 甲钴胺 单唾液酸四己糖神经节苷脂 |
| 英文关键词: Diabetic peripheral neuropathy Methyl cobalamin GM1 |
| 基金项目: |
|
| Hits: 408 |
| Download times: 227 |
| 中文摘要: |
| 摘要 目的：探讨不同剂量甲钴胺联合单唾液酸四己糖神经节苷脂（GM1）治疗糖尿病周围神经病变的疗效。方法：收取2013年3月至2016年3月我院收治的糖尿病周围神经病变患者116例作为研究对象，按照随机数字表法分为A、B组各58例。A组患者使用高剂量甲钴胺联合GM1治疗，B组患者使用常规剂量甲钴胺联合GM1治疗。对两组治疗效果、神经电生理、不良反应以及患者生活质量进行观察与比较。结果：A组患者治疗显效率和总有效率分别为63.79 %和96.55 %，显著高于B组的39.66 %和84.48 %，差异有统计学意义（P<0.05）。治疗后两组患者腓神经及正中神经运动神经传导速度（MCV）以及感觉神经传导速度（SCV）均显著提高，与治疗前相比有显著差异，且A组变化幅度明显高于B组，差异有统计学意义（P<0.05）。A组不良反应发生率为6.70 %，B组为3.45 %，两组相较差异不显著（P>0.05）。治疗后A组生活质量得分高于B组，差异有统计学意义（P<0.05）。结论：高剂量甲钴胺联合GM1治疗糖尿病周围神经病变与常规剂量相比具有更好的疗效，有助于患者生活质量的提高，值得临床推广应用。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical effect of different dose of methyl cobalamin combined ganglioside GM1 in treatment of diabetic peripheral neuropathy patients. Methods: 116 patients with diabetic peripheral neuropathy patients accepted in our hospital from March 2013 to March 2016 were selected and randomly divided into group A and B with 58 cases in each group. The patients in group A were given high dose methyl cobalamin combined GM1, and the patients in group B were given regular dose methyl cobalamin combined GM1. The clinical effect, neuroelectrophysiology, adverse reactions and life quality of two groups were observed and com- pared. Results: The remarkable effect rate and total efficiency of group A were 63.79 % and 96.55 % respectively, obviously higher than 39.66 % and 84.48 % of group B with statistical significance(P<0.05). motor nerve conduction velocity (MCV) and sensory nerve con- duction velocity (SCV) of sural nerves and median nerve of two groups after treatment were obviously better than before, and the indexes were improved much better in group A than those of group B with statistical significance (P<0.05). The adverse reaction rate of group A was 6.70 %, of group B was 3.45 %, and the difference was not statistically significant (P>0.05). The life quality score of group A after treatment was much higher than that of group B (P<0.05). Conclusion: Using high dose methyl cobalamin combined GM1 has good ef- fect in treatment of diabetic peripheral neuropathy patients, which is good at life quality improvement and worth of clinical applications. |
|
View Full Text
View/Add Comment Download reader |
| Close |
